PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer
Public ClinicalTrials.gov record NCT01737619. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Prospective Evaluation of Lymph Node Metastasis at the Time of Surgical Staging for High Risk Endometrial Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This clinical trial studies positron emission tomography (PET)/computed tomography (CT) and lymph node mapping in finding lymph node metastasis in patients with endometrial cancer that is at high risk of spreading. A PET/CT scan is a procedure that combines the pictures from a PET scan and a CT scan, which are taken at the same time from the same machine. The combined scans give more detailed pictures of areas inside the body than either scan gives by itself. Lymph node mapping uses a radioactive dye, called indocyanine green solution, to identify lymph nodes that may contain cancer cells. PET/CT and sentinel lymph node mapping may be better ways than surgery to identify cancer in the lymph nodes.
Study identification
- NCT ID
- NCT01737619
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 101 participants
Conditions and interventions
Conditions
Interventions
- Computed Tomography Procedure
- Indocyanine Green Solution Drug
- Laboratory Biomarker Analysis Other
- Lymph Node Mapping Procedure
- Lymphadenectomy Procedure
- Positron Emission Tomography Procedure
Procedure · Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 2, 2013
- Primary completion
- Apr 29, 2025
- Completion
- Dec 30, 2028
- Last update posted
- May 3, 2026
2013 – 2028
United States locations
- U.S. sites
- 7
- U.S. states
- 1
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Lyndon Baines Johnson General Hospital | Houston | Texas | 77026-1967 | — |
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
| The Woman's Hospital of Texas | Houston | Texas | 77054 | — |
| MD Anderson Regional Care Center-Katy | Houston | Texas | 77094 | — |
| MD Anderson Regional Care Center-Bay Area | Nassau Bay | Texas | 77058 | — |
| MD Anderson Regional Care Center-Sugar Land | Sugar Land | Texas | 77478 | — |
| MD Anderson Regional Care Center-The Woodlands | The Woodlands | Texas | 77384 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01737619, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 3, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01737619 live on ClinicalTrials.gov.